title: Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
abstract: Pulmonary inhalation chemotherapeutic drug delivery offers many advantages for lung cancer patients in comparison to conventional systemic chemotherapy. Inhalable particles are advantageous in their ability to deliver drug deep in the lung by utilizing optimally sized particles and higher local drug dose delivery. In this work, spray-dried and co-spray dried inhalable lung surfactant-mimic PEGylated lipopolymers as microparticulate/nanoparticulate dry powders containing paclitaxel were rationally designed via organic solution advanced spray drying (no water) in closed-mode from dilute concentration feed solution. Dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) with varying PEG chain length were mixed with varying amounts of paclitaxel in methanol to produce co-spray dried microparticles and nanoparticles. Scanning electron microscopy showed the spherical particle morphology of the inhalable particles. Thermal analysis and X-ray powder diffraction confirmed the retention of the phospholipid bilayer structure in the solid-state following spray drying, the degree of solid-state molecular order, and solid-state phase transition behavior. The residual water content of the particles was very low as quantified analytically Karl Fisher titration. The amount of paclitaxel loaded into the particles was quantified which indicated high encapsulation efficiencies (43-99%). Dry powder aerosol dispersion performance was measured in vitro using the Next Generation Impactor (NGI) coupled with the Handihaler dry powder inhaler device and showed mass median aerodynamic diameters in the range of 3.4-7 μm. These results demonstrate that this novel microparticulate/nanoparticulate chemotherapeutic PEGylated phospholipid dry powder inhalation aerosol platform has great potential in lung cancer drug delivery.
authors.affiliation: University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences - Drug Development Division, Lexington, KY 40536-0596, USA.
authors.forename: Samantha A
authors.initials: SA
authors.lastname: Meenach
authors.forename: Kimberly W
authors.initials: KW
authors.lastname: Anderson
authors.forename: J
authors.initials: J
authors.lastname: Zach Hilt
authors.forename: Ronald C
authors.initials: RC
authors.lastname: McGarry
authors.forename: Heidi M
authors.initials: HM
authors.lastname: Mansour
mesh_terms: D015060:1,2-Dipalmitoylphosphatidylcholine / Q000737:chemistry*; D000280:Administration, Inhalation; D000336:Aerosols; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry*; D003890:Desiccation / Q000379:methods; D058995:Dry Powder Inhalers; D008175:Lung Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry*; D010316:Particle Size; D010714:Phosphatidylethanolamines / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D013501:Surface-Active Agents / Q000737:chemistry*; D013678:Technology, Pharmaceutical
chemical_list: D000336:Aerosols; D000972:Antineoplastic Agents, Phytogenic; C102564:DPPE-PEG2000; D010714:Phosphatidylethanolamines; D013501:Surface-Active Agents; D015060:1,2-Dipalmitoylphosphatidylcholine; D011092:Polyethylene Glycols; D017239:Paclitaxel
keywords: Biocompatible biodegradable lipopolymers; Dry powder inhaler (DPI); Lung surfactant; Nanomedicine; Nanotechnology; Respiratory drug delivery